INTRODUCTION AND AIMS:
Albumin and Glomerular Filtration Rate (GFR) are known markers of Cardiovascular Disease (CVD) risk and renal function in chronic kidney disease (CKD) and diabetes mellitus (DM) patient populations. A strong relationship exists between high or constant albumin levels in blood and improved renal function. Additionally, albumin levels have been associated with (CVD) risk and major adverse cardiovascular events (MACE) outcomes in DM and CKD patients. Apabetalone is a first-in-class orally active bromodomain and extraterminal domain ( BET) inhibitor with BD2 selectivity. Apabetalone in phase 2 studies showed a MACE-reduction in patients with a history of CVD accounted for by effects in DM patients. BET inhibition by apabetalone has been shown to regulate activation of pathways that underlie CVD, DM and CKD including, vascular inflammation and mineralization, coagulation and complement. Additionally, an improvement of estimated GFR has been reported in a subpopulation analysis of CVD patients with baseline eGFR < 60 ml/min/1.73m² (n=35 in apabetalone group; n=13 placebo group) from the phase 2 clinical trials.

METHODS:
In the phase 2 clinical studies, high risk CVD patients (n=331 in apabetalone group; n=168 in placebo group) were treated with 100 mg b.i.d apabetalone or placebo for 6 months. Patients with a history of DM (n=127 in apabetalone group; n=65 in placebo group) were evaluated as a subgroup as well as patients with baseline eGFR < 60 ml/min/1.73m² (n=35 in apabetalone group; n=13 placebo group). Serum albumin was collected during trial visits at screening, 3 months and 6 months. Analysis was performed in each group assessing changes in albumin from screening to 3 and 6 month visits. Plasma Alkaline phosphatase (ALP) activity was assessed at the same time points.

RESULTS:
Following 6 months of apabetalone treatment, a 1.3% improvement in serum albumin level versus placebo (p<0.05) was observed in all CVD patients. In the DM subgroup, a 2.1% increase in albumin versus placebo (p<0.10) was observed. In patients with baseline eGFR<60 ml/min/1.73m², the difference in albumin between those on apabetalone treatment and those receiving placebo was 5.2% (p=0.15). Additionally, an increase in eGFR of 3.4% (p=0.04 vs. baseline) was observed in these patients compared to a decrease of 5.9% in the placebo group. The changes in plasma ALP activity for apabetalone and placebo were -14.0% vs. -6.3%, respectively (p<0.05).

CONCLUSIONS:
In all CVD patients, BET inhibition via apabetalone significantly increased serum albumin levels versus placebo, with the similar or more pronounced numerical effects in the smaller DM and eGFR <60 ml/min/1.73m patients. The parallel observation of increase in eGFR by apabetalone treatment suggests further potential for renal function improvement in patients with CKD and high risk CVD. Apabetalone is currently being evaluated in the phase 3 clinical trial, BETonMACE, which is targeting acute coronary syndrome patients with DM in which estimated 15% will have CKD.